Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company...
Vaccine
New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis
Infusion related reactions in patients receiving 30-minute BRIUMVI infusions were all mild (Grade 1) and resolved completely Data also demonstrate...
New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50...
Gavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of Mpox Vaccines for Africa
The advance purchase agreement (APA) will be funded by Gavi’s First Response Fund, a mechanism created after the COVID-19 pandemic...
Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada
To potentially include adolescents and antibody persistence up to two years Saint Herblain (France), September 18, 2024 – Valneva SE...
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
HALIFAX, Nova Scotia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”),...
Bioinformatics Market to Grow by USD 13.2 Billion (2024-2028) Boosted by Lower Genetic Sequencing Costs, Powered by AI – Technavio Report
NEW YORK, Sept. 17, 2024 /PRNewswire/ -- Report on how AI is driving market transformation- The global bioinformatics market size is...
HDT Bio to Help Spearhead RNA Vaccine Development in National Pandemic Preparedness Initiative
HDT bio's Rapid-Response Roadmap for RNA vaccines (R4) project granted a five-year subaward for $2M per year SEATTLE, Sept. 17,...
Hackensack Meridian Hackensack University Medical Center is the First Hospital in the World to Use the Artificial Intelligence-Powered HYDROS™ Robotic System to perform Aquablation® Therapy to Treat Prostate Enlargement
HACKENSACK, N.J., Sept. 17, 2024 /PRNewswire/ -- On the morning of Wednesday, September 4, 2024, Hackensack Meridian Hackensack University Medical...
Zoetis to Introduce First Cartridge-Based AI-Powered Hematology Analyzer
Zoetis is introducing Vetscan OptiCell™ as it continues to transform diagnostics with its suite of integrated products and servicesThe cartridge-based hematology...
Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
SPIKEVAX® is the first updated COVID-19 vaccine authorized in Canada for 2024-2025, offering a timely solution to help protect Canadians...
Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application
- Recurring and Accelerated Receipt of Order Reflects Customer Commitment to Linea DNA - STONY BROOK, NY / ACCESSWIRE /...
New England Biolabs Awarded Additional LEED® Building Certification for Expansion to its Laboratory Facility
NEB's recently developed 100,000 square foot expansion to its production facility recognized by the U.S. Green Building Council IPSWICH, Mass.,...
Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies
JERUSALEM, Israel, Sept. 16, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company specializing...
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the...
CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy84% of immune...
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing...
FDA Authorizes First Over-the-Counter Hearing Aid Software
SILVER SPRING, Md., Sept. 12, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration authorized the first over-the-counter (OTC)...
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all...
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola
GAITHERSBURG, Md., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a contract...